Safety and efficacy of upfront autologous transplantation as a consolidation therapy for progressive nasal type extranodal NK/T-cell lymphoma
10.3760/cma.j.cn421203-20220712-00173
- VernacularTitle:自体移植一线巩固治疗非局限期鼻型结外NK/T细胞淋巴瘤
- Author:
Fangfang YUAN
1
;
Yuewen FU
;
Jian ZHOU
;
Minghui LI
;
Gangping LI
;
Xudong WEI
Author Information
1. 郑州大学附属肿瘤医院，河南省肿瘤医院血液科，郑州 450008
- Keywords:
Hematopoietic stem cell transplantation;
Autologous transplantation;
Extranodal NK/T cell lymphoma
- From:
Chinese Journal of Organ Transplantation
2022;43(10):611-616
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of upfront autologous hematopoietic stem cell transplantation(auto-HSCT)as a consolidation therapy of progressive nasal type extranodal NK/T-cell lymphoma, (ENKL).Methods:From January 2012 to June 2021, clinical data were retrospectively reviewed for 28 patients with advanced-stage ENKL on chemotherapy of asparaginase-containing regimen followed by upfront auto-HSCT as a consolidation therapy.The median age at transplantation was 34.5(14-61)years.There were 19 males and 9 females.Clinical types were nasal(n=22)and non-nasal(n=6). Clinical stages were Ann Arbor III(n=15)and IV(n=13). Clinical risks were intermediate(n=8)and high(n=20)according to the Prognostic Index for Natural-Killer cell lymphoma-Epstein-Barr virus(PINK-E).Results:Hematopoietic reconstruction was performed.Median time of neutrophil engraftment was 10(8-17)days and 13(10-22)days for platelet.Median follow-up time was 59.5 months and 5-year OS/PFS 70.0%(95% CI: 50.60%-89.40%)and 59.1%(95% CI: 39.11%-79.10%). And 5-year cumulative recurrence and non-recurrence mortality rates were 35.42%(95% CI: 19.11%-59.39%)and 4.2%(95% CI: 2.16%-29.87%). Conclusions:Asparaginase-based chemotherapy followed by auto-HSCT is both safe and efficacious for progressive ENKTL.
